Book a meeting
DO-BO

Beyond the CE Mark: How can we achieve Medtech Reimbursement in France, Dr. Benoit Salaun?

Dive deep into the heart of French market access with Dr. Stefan Walzer and Dr. Benoit Salaun on this episode of the Map Podcast. As experts in their fields, they dissect the intricacies of the French healthcare system, focusing on medical device reimbursement, and revealing the critical steps to success in this competitive landscape.

This episode is a goldmine for healthcare professionals, medtech innovators, and market access strategists seeking to penetrate the French market effectively. Gain unparalleled insights into securing the optimal position and price for your medical device in France. Embark on your journey to mastering French market access with expert guidance—listen today!

Related

Why Should Pharma and MedTech Innovators Look at New Zealand, Julius Ohrnberger?

By

Stefan Walzer

Tune in to this new episode of MAP to explore New Zealand’s unique healthcare and reimbursement landscape with Dr. Stefan Walzer and health economist Dr. Julius Ohnberger. Learn how PHARMAC combines HTA and payer roles, why equity and Māori health outcomes are central to market access and what global pharma can gain from launching in […]

Are We Ready for a Cultural Shift Toward AI in Pharma, Elizabeth Shanahan?

By

Stefan Walzer

In this brand new episode of MAP – the Market Access Podcast, Dr. Stefan Walzer sits down with Elizabeth Shanahan, AI Strategy Lead at Sanofi, for a refreshingly honest conversation on the real-world implementation of artificial intelligence in pricing, evidence generation, and HTA processes. From streamlining evidence generation to enhancing pricing strategies and dossier creation, […]

What Can Europe and the U.S. Learn from Each Other on Market Access, Anne Loos?

By

Stefan Walzer

Tune in to this new episode of MAP, the Market Access Podcast, where Dr. Stefan Walzer is joined by Anne Loos from Wickenstones, to explore the evolving landscape of U.S. market access and reimbursement. The U.S. reimbursement landscape is changing — driven by AI, global influences with the European JCA and political programs such as […]